This study compared the PlusoptiX A12 to a comprehensive ophthalmic investigation. This was a three-month study of 219 (438 eyes) subjects with a mean age of 72 months. The A12 referred 101 of 219 (46%) patients for potential amblyopia. Ophthalmic investigation found 87 (40%) with amblyopia or amblyopia risk factors. On comparison of the A13 to ophthalmic investigation, testability rate was 84.47%, sensitivity of 93.02%, specificity of 84.96%, false positives of 9.13%, false negatives of 2.74%, positive predictive value of 80% and negative predictive value of 94.96%. The authors conclude the A13 is a user-friendly and time-efficient screening device with high sensitivity for detecting refractive amblyopia risk factors. Further increase in sensitivity may be possible with combination of A12 and the alternate cover test.
Screening with PlusoptiX
Reviewed by Fiona Rowe
Critical assessment of an ocular photoscreener.
CONTRIBUTOR
Fiona Rowe (Prof)
Institute of Population Health, University of Liverpool, UK.
View Full Profile
